skip to Text-Only Versionskip banner navigation
National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Chronic Lymphocytic Leukemia (PDQ®): Treatment
Patient VersionHealth Professional VersionEn españolLast Modified: 07/17/2007
skip to content



General Information






Stage Information






Treatment Option Overview






Stage 0 Chronic Lymphocytic Leukemia






Stage I, II, III, and IV Chronic Lymphocytic Leukemia







Refractory Chronic Lymphocytic Leukemia






Changes to This Summary (07/17/2007)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
Questions about cancer?

1-800-4-CANCER

NCI Highlights
Report Finds Cancer Death Rate Decline Doubling

October Is National Breast Cancer Awareness Month

The Nation's Investment in Cancer Research FY 2008

Statement on Fiscal Year 2008 Budget Request

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2005 Update

NCAB Working Group Report on Biomedical Technology

Past Highlights
You CAN Quit Smoking Now!
HPV Vaccines for Cervical Cancer
Refractory Chronic Lymphocytic Leukemia

Clinical trials are appropriate and should be considered when possible.[1] In small studies, response rates of more than 40% have been reported for lenalidomide [2] and flavopiridol.[3][Level of evidence: 3iiiDiii] Information about ongoing clinical trials for patients with refractory chronic lymphocytic leukemia is available from the NCI Web site. Bone marrow and peripheral stem cell transplantations are under clinical evaluation.[4-10]

References

  1. Byrd JC, Rai KR, Sausville EA, et al.: Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 25 (1): 65-74, 1998.  [PUBMED Abstract]

  2. Chanan-Khan A, Miller KC, Musial L, et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (34): 5343-9, 2006.  [PUBMED Abstract]

  3. Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2): 399-404, 2007.  [PUBMED Abstract]

  4. Dreger P, Brand R, Milligan D, et al.: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (6): 1029-33, 2005.  [PUBMED Abstract]

  5. Schetelig J, Thiede C, Bornhauser M, et al.: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 (14): 2747-53, 2003.  [PUBMED Abstract]

  6. Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (8): 2600-2, 2004.  [PUBMED Abstract]

  7. Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (15): 3433-8, 2005.  [PUBMED Abstract]

  8. Khouri IF, Keating MJ, Saliba RM, et al.: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4 (3): 217-21, 2002.  [PUBMED Abstract]

  9. Doney KC, Chauncey T, Appelbaum FR, et al.: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (10): 817-23, 2002.  [PUBMED Abstract]

  10. Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23 (24): 5788-94, 2005.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >

skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov